Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said Monday their developing VEGF Trap-Eye drug met key treatment goals in a late-stage study on macular edema patients.
Specifically, the study focused on patients with macular edema because of central retinal vein occlusion, or blockage of retinal veins. Macular edema is a condition in which the macula, or central part of the retina, swells because fluid leaks or builds up.
In the 114-person study, the drug prompted vision improvements. The study showed that 56.1 percent of patients receiving the injections on a monthly basis gained at least 15 letters in vision tests.
For more:Regeneron, Bayer cite positive eye drug study - Bloomberg
No comments:
Post a Comment